You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The Capitainer qDBS solution is being developed to ensure that an exact sample volume of 10µl of blood is collected, and to enable convenient and quantitative blood sampling at the fingertip.
The firm plans to use the cash to support commercial expansion of its NIPT to all US states and fund R&D for future diagnostic tests, including liquid biopsies.
La Jolla, California-based DermTech has agreed to sell common and preferred stock to a number of undisclosed institutional investors.
The Series B round, which includes new and existing investors, follows the Belgian firm's completion of a €7.7 million private placement in 2016.
The company said the financing brings it a step closer to fulfilling its vision of enabling new-generation tissue analytics tests based on its microfluidic technology.
The University of Utah spinout said it will use the funding to enhance and expand its NGS-based Explify microbe identification platform and support its lab.
The firm has opened a $10 million Series A financing round that it expects to close in late summer to support running clinical studies for its assay.
The firm said it will use the funds to advance development of its HostDx immune response gene expression tests for acute infections and sepsis.
The funding will be used to bring to market Oklahoma City-based Progentec's products for CLIA labs, as well as its digital technologies for managing lupus.
Developers pointed to some success, but they also noted that more at-home tests need to demonstrate higher levels of performance and affordability.